factor VII

(redirected from Novoseven)
Also found in: Dictionary, Thesaurus, Medical.
Related to Novoseven: FEIBA, Novoeight

factor VII

[′fak·tər ′se·vən]
(biochemistry)
A procoagulant, related to prothrombin, that is involved in the formation of a prothrombin-converting principle which transforms prothrombin to thrombin. Also known as stable factor.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Recombinant Factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with Factor VIII and IX inhibitors.
But the MoD said NovoSeven is used only as a last resort.
NovoSeven was licensed in 1999 for use to stem bleeding in haemophiliacs but is still undergoing trials for use on trauma patients with severe wounds.
NovoSeven has been used to treat just a handful of injured troops and in one case is said to have saved a soldier's life, the MoD insisted.
The Ministry of Defence is giving soldiers an experimental blood clotting drug called NovoSeven, the Guardian reports.
Many PPH cases have a major component of acquired coagulopathy, making rFVIIa (Novoseven) a treatment option, indicated for hemophilia A or B, with inhibitors of factor VII or factor IX.
Mayer and a team of physicians in North America, Europe, Asia, and Australia treated 303 bleeding-stroke patients with an intravenous drug called recombinant activated factor VII (rFVIIa), which certain hemophilia patients receive under the brand name NovoSeven. The researchers gave a placebo infusion to 96 other patients with bleeding strokes.
The phase II dose-finding study, conducted at 73 centers worldwide, randomized 400 patients to either placebo or one of three dosages of the recombinant clotting factor rVIIa (NovoSeven).
El riesgo es menor en pacientes que reciben concentrados de factor IX (13) y se puede usar junto a factor VII recombinante (NovoSeven).
For 2018, sales growth is expected to be 2-5% as Novoeight, N8-GP, and N9-GP should compensate for the potential losses of NovoSeven and Norditropin in the biopharmaceuticals segment, and Fiasp, Semaglutide, Saxenda, and Tresiba should compensate the potential losses of modern insulins in the diabetes segment.
(9.) Lusher JM: Recombinant factor Vila (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.